Related Experiment Videos

[Bronchiectasis in pediatrics, diagnosis approach and management]

Francisco Alvarez Caro1, Angela Gómez Farpón, Paloma Ruiz del Árbol Sánchez

  • 1Servicio de Pediatría, Hospital Carmen y Severo Ochoa, Cangas del Narcea, Asturias, España. franciscoalvarez130@msn.com

Archivos Argentinos De Pediatria
|February 7, 2012
PubMed

Insights

Bronchiectasis is a significant global health issue. This review focuses on diagnosing non-cystic fibrosis bronchiectasis to identify underlying causes and guide targeted treatments.

Area of Science:

  • Pulmonology
  • Medical Diagnostics

Context:

  • Bronchiectasis remains a prevalent respiratory condition worldwide.
  • Cystic fibrosis is a primary cause, but numerous other factors contribute to non-cystic fibrosis bronchiectasis.
  • Accurate diagnosis is crucial for effective management.

Purpose:

  • To review the diagnostic evaluation of bronchiectasis, excluding cystic fibrosis.
  • To outline a systematic approach for identifying the specific etiology of non-cystic fibrosis bronchiectasis.
  • To emphasize the importance of etiology-specific treatment.

Summary:

  • This article reviews bronchiectasis, focusing on non-cystic fibrosis cases.
  • It highlights the need for systematic diagnostic evaluation beyond initial medical history and imaging.
  • The goal is to determine the underlying cause for targeted therapy.

Impact:

  • A structured diagnostic approach aids in identifying diverse causes of bronchiectasis.
  • Understanding the etiology allows for personalized treatment strategies.
  • This review provides a framework for clinicians managing non-cystic fibrosis bronchiectasis.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: